New Technologies Improve Prostate Biopsies

One in nine men will be diagnosed with prostate cancer during his lifetime, according to the American Cancer Society. Prostate cancer affects approximately 200,000 men in the United States each year. While 34,700 of those men will die from the disease in 2023, that number has been declining each year, thanks to advancements in early detection and new, aggressive treatment options.

At Minnesota Urology, we use two innovative technologies to improve the diagnosis of prostate cancer. ExactVu is a new, high-resolution micro-ultrasound technology for targeted biopsies of the prostate, improving the resolution of traditional ultrasound by more than 300%. Minnesota Urology is now using this technology to provide our patients with quicker, more accurate, and more cost-effective biopsy results.

We also are one of the few urology practices in the area to use the UroNav MRI-assisted, ultrasound-guided biopsy technique for men with rising PSA levels and negative biopsies. This remarkable technology provides a new level of accuracy because of its ability to detect cancer in hard-to-find areas of the prostate. As a result, it can reduce the need for multiple biopsies.

Physicians at Minnesota Urology are on the leading edge of prostate cancer diagnosis and treatment options. We welcome the opportunity to provide care for you.

Skip to toolbar